Simple Summary Apalutamide, darolutamide and enzalutamide are androgen-receptor
signaling inhibitors proved to be useful in patients with nonmetastatic castration-resistant …

Simple Summary Several strategies have demonstrated the ability to improve the survival of
patients with both metastatic and nonmetastatic prostate cancer. The old backbone of …

Background Diagnosis of metastatic castrate resistant prostate cancer (mCRPC) with current
biomarkers is difficult and often results in unnecessary invasive procedures as well as over …

The aim of this study is to elucidate the clinical significance of prostate-specific membrane
antigen (PSMA) expression in circulating tumor cells (CTCs) from castration-resistant …

In advanced prostate cancer, access to recent diagnostic tissue samples is restricted and
this affects the analysis of the association of evolving biomarkers such as AR-V7 with …

Androgen receptor splice variant-7 (AR-V7) expression in circulating tumor cells (CTCs) in
metastatic castration-resistant prostate cancer (mCRPC) is associated with abiraterone and …

Simple Summary Circulating tumor cells (CTCs) are a promising biomarker for the risk of
prostate cancer aggressiveness and metastasis and play a role in the processes of tumor …

Simple Summary The development of biomarkers that can predict the effectiveness of
treatments for metastatic castration-resistant prostate cancer (mCRPC) has been a recent …

Background Nowadays, the incidence rate of advanced and metastatic prostate cancer at
the first time of diagnosis grows higher in China yearly. At present, androgen deprivation …

In the last decade, treatment for castration-resistant prostate cancer has changed markedly,
impacting symptom control and longevity for patients. However, a large proportion of cases …